Aggressive lymphoma: improving treatment outcome with rituximab.

abstract：:In an effort to develop new agents and molecular targets for the treatment of cancer, aspargine-glycine-arginine (NGR)-targeted liposomal doxorubicin (TVT-DOX) is being studied. The NGR peptide on the surface of liposomal doxorubicin (DOX) targets an aminopeptidase N (CD13) isoform, specific to the tumor neovasculatur...

journal_title：Anti-cancer drugs

authors： Garde SV,Forté AJ,Ge M,Lepekhin EA,Panchal CJ,Rabbani SA,Wu JJ

更新日期：2007-11-01 00:00:00

abstract：:We examined the anti-tumor activity and structure-activity requirements of omega-hydroxy fatty acids (omega-HFAs) on the human melanoma cell line G361. The omega-hydroxystearic acid (omega-HSA) had strong growth-inhibiting and cytotoxic activity. Although omega-hydroxypalmitic acid (omega-HPA) also had growth-inhibiti...

journal_title：Anti-cancer drugs

authors： Abe A,Sugiyama K

更新日期：2005-06-01 00:00:00

abstract：:Genome profiling approaches such as cDNA microarray analysis and quantitative reverse transcription polymerase chain reaction are playing ever-increasing roles in the classification of human cancers and in the discovery of biomarkers for the prediction of prognosis in cancer patients. Increasing research efforts are a...

journal_title：Anti-cancer drugs

authors： Parissenti AM,Hembruff SL,Villeneuve DJ,Veitch Z,Guo B,Eng J

更新日期：2007-06-01 00:00:00

abstract：:Patients with metastatic squamous cell cancer of the head and neck (SCCHN) have a poor prognosis, with most patients surviving less than a year. Immunotherapy (IO) is changing the natural history of the disease and programmed death-ligand 1 (PD-L1) inhibitors are showing notable improvements in survival with a more fa...

journal_title：Anti-cancer drugs

authors： Cabezas-Camarero S,Cabrera-Martín MN,Pérez-Segura P

更新日期：2019-02-01 00:00:00

abstract：:The prognosis of children with high-grade glioma or high-risk neuroblastoma remains poor. Cilengitide is a selective antagonist of αvβ3 and αvβ5 integrins, which are involved in tumor growth and development of metastasis. We have evaluated the effects of cilengitide on pediatric glioma and neuroblastoma cell lines for...

journal_title：Anti-cancer drugs

authors： Leblond P,Dewitte A,Le Tinier F,Bal-Mahieu C,Baroncini M,Sarrazin T,Lartigau E,Lansiaux A,Meignan S

更新日期：2013-09-01 00:00:00

abstract：:A toxicology study of DENSPM was carried out in rats by multiple (once daily for 5 days) intravenous injection. Doses of 12.5, 25 and 50 mg DENSPM/kg were well tolerated. Infusion of 100 mg DENSPM resulted in distressing physical signs, including labored breathing, convulsive movements and acute death. There were no e...

journal_title：Anti-cancer drugs

authors： Kanter PM,Bullard GA,King JM

更新日期：1994-08-01 00:00:00

abstract：:Non-resectable biliary tract cancer is associated with poor prognosis due to widespread resistance to chemotherapeutic agents and radiotherapy. It is therefore essential to explore new therapeutic approaches like the inhibition of tyrosine kinases. The aim of this study was to determine the expression of c-kit and pla...

journal_title：Anti-cancer drugs

authors： Wiedmann M,Kreth F,Feisthammel J,Deininger M,Mössner J,Caca K

更新日期：2003-10-01 00:00:00

abstract：:The development of a new anticancer drug with a novel structure and unique mechanism of action is an important event, especially when the drug plays a clear role in improving the outcome for cancer patients. No drug fits this description better than Taxol. However, during the early phases of its development, there was...

journal_title：Anti-cancer drugs

authors： Wani MC,Horwitz SB

更新日期：2014-05-01 00:00:00

abstract：:The primary aim of this randomized trial was to determine response rate and progression-free survival following chemotherapy in patients with platinum-resistant recurrent ovarian cancer, who had been treated according to an ATP-based tumour chemosensitivity assay in comparison with physician's choice. A total of 180 p...

journal_title：Anti-cancer drugs

authors： Cree IA,Kurbacher CM,Lamont A,Hindley AC,Love S,TCA Ovarian Cancer Trial Group.

更新日期：2007-10-01 00:00:00

abstract：:Cyclosporin A (CsA) is a calcium antagonist and can enhance the efficacy of some protein drugs, but its mechanism remains unknown. In this study, MAP30, a ribosome-inactivating protein reported to have apoptotic effects on cancer cells, was fused with S3, an epidermal growth factor receptor (EGFR)-targeting peptide. I...

journal_title：Anti-cancer drugs

authors： Song ZT,Zhang LW,Fan LQ,Kong JW,Mao JH,Zhao J,Wang FJ

更新日期：2018-09-01 00:00:00

abstract：:Gonadotropin releasing hormone (GnRH) and its analogs inhibit the growth of hormone-dependent tumors in vivo and in vitro. The inhibition of growth and proliferation of tumor cells in vitro by GnRH and its analogs indicates that the tumor suppressing effect of the hormone is only partially due to suppression of pituit...

journal_title：Anti-cancer drugs

authors： Kakar SS,Nath S,Bunn J,Jennes L

更新日期：1997-04-01 00:00:00

abstract：:Paeonol, a major phenolic component of Moutan Cortex, is known to have antitumor effects through an unknown mechanism. In this study, we tried to elucidate the anticancer effects of paeonol on human hepatocellular carcinoma (HCC) cell lines BEL-7404, SMMC-7721, and MHCC97-H in vitro. Using the 3-[4,5-dimethylthiazol-2...

journal_title：Anti-cancer drugs

authors： Chunhu Z,Suiyu H,Meiqun C,Guilin X,Yunhui L

更新日期：2008-04-01 00:00:00

abstract：:Cerebral gliomas have a poor survival time even after multimodal treatment, because of the unavoidable recurrence of tumor. Several trials with a combination of old and new chemotherapics have been performed, but survival time remains generally less than 12 months. Tamoxifen (TAM) has recently been shown to inhibit th...

journal_title：Anti-cancer drugs

authors： Mastronardi L,Puzzilli F,Ruggeri A

更新日期：1998-08-01 00:00:00

abstract：:Creatine kinase (CK), a key enzyme of cellular energetics, has been implicated in tumorigenesis. Cyclocreatine (CCr), which forms a stable phosphagen with a reduced rate of ATP regeneration through CK, inhibits the growth of many solid tumors. We report that CCr induces the formation of unusually stable microtubules t...

journal_title：Anti-cancer drugs

authors： Martin KJ,Vassallo CD,Teicher BA,Kaddurah-Daouk R

更新日期：1995-06-01 00:00:00

abstract：:Lipoplatin, currently under phase III evaluation, is a novel liposomal cisplatin formulation highly effective against cancers. Lipoplatin has eliminated or reduced the systemic toxicity frequently seen for cisplatin. The objective of the present study was to determine whether the cytotoxic effect of lipoplatin is depe...

journal_title：Anti-cancer drugs

authors： Fedier A,Poyet C,Perucchini D,Boulikas T,Fink D

更新日期：2006-03-01 00:00:00

abstract：:Results are summarized for two phase II studies of docetaxel as first-line therapy for advanced squamous cell carcinoma of the head and neck (SCCHN) and one study of docetaxel as second-line therapy for advanced soft tissue sarcomas. In all three studies, docetaxel was administered at a dose of 100 mg/m2 by intravenou...

journal_title：Anti-cancer drugs

authors： Verweij J

更新日期：1995-07-01 00:00:00

abstract：:Chemotherapy for breast cancer is given on the basis of empirical information from clinical trials, an approach which falls to take into account the known heterogeneity of chemosensitivity between patients. Previous attempts to determine chemosensitivity ex vivo have been disappointing, but in this study results from ...

journal_title：Anti-cancer drugs

authors： Cree IA,Kurbacher CM,Untch M,Sutherland LA,Hunter EM,Subedi AM,James EA,Dewar JA,Preece PE,Andreotti PE,Bruckner HW

更新日期：1996-08-01 00:00:00

abstract：:Anomalous gene regulation, dictated by epigenetic modifications, is a universal characteristic of cancer cells. Histone deacetylases (HDACs) are an important class of enzymes that influence gene expression by the removal of acetyl groups from histones leading to chromatin remodeling and transcriptional suppression of ...

journal_title：Anti-cancer drugs

authors： Jazirehi AR

更新日期：2010-10-01 00:00:00

abstract：:(E)-2'-deoxy-2'-(fluoromethylene) cytidine (MDL101,731) is a new deoxycytidine analog which shows potent antitumor activity against several human tumor models. We previously showed that MDL101,731 inhibited human ribonucleotide reductase (RNR) in HeLa S3 human cervical carcinoma cells. Recently, it has been reported t...

journal_title：Anti-cancer drugs

authors： Kanazawa J,Takahashi T,Akinaga S,Tamaoki T,Okabe M

更新日期：1998-08-01 00:00:00

abstract：:Glucocorticosteroids (GC) play an important role in the treatment of neuro-oncologic patients. GC are used for the management of malignant brain tumors, either primary of secondary, neoplastic epidural spinal cord compression (NESC), as adjuvant chemotherapy of some central nervous system tumors and perioperatively in...

journal_title：Anti-cancer drugs

authors： Koehler PJ

更新日期：1995-02-01 00:00:00

abstract：:Docetaxel is a new antimicrotubule agent that induces a predominantly sensory neuropathy that is mild in most patients. This prospective study was performed to determine if corticosteroid co-medication reduces the incidence and severity of docetaxel-induced neuropathy. Two groups of patients treated with docetaxel in ...

journal_title：Anti-cancer drugs

authors： Pronk LC,Hilkens PH,van den Bent MJ,van Putten WL,Stoter G,Verweij J

更新日期：1998-10-01 00:00:00

abstract：:Since their addition to paclitaxel in the oncologists' armamentarium in the early 1990s, several new taxane formulations have been developed. Besides docetaxel and nab-paclitaxel, new analogs with better therapeutic profiles are being investigated. The goals of this next generation of taxanes are to improve the toxici...

journal_title：Anti-cancer drugs

authors： Muggia F,Kudlowitz D

更新日期：2014-05-01 00:00:00

abstract：:The mechanism of action of a synthetic compound--2,2'-bipyridyl-6-carbothioamide--was investigated by developing tumor lines resistant to it (P388-R1.5 and P388-R4). P388-R4 is resistant to inhibitors of ribonucleotide reductase (RR) while no resistance was observed to antitumor drugs having other targets (except to b...

journal_title：Anti-cancer drugs

authors： Nocentini G,Federici F,Armellini R,Franchetti P,Barzi A

更新日期：1990-12-01 00:00:00

abstract：:The objective of this study was to detect the effect of NADPH oxidase (NOX) inhibition on metastasis of lung cancer. Primary human lung cancer cells were isolated from surgical tissues using the Cancer Cell Isolation Kit. Invasion was detected using the BD Biocoat Matrigel Invasion Chamber assay. Expressions of microR...

journal_title：Anti-cancer drugs

authors： Yan S,Liu G,Pei C,Chen W,Li P,Wang Q,Jin X,Zhu J,Wang M,Liu X

更新日期：2015-04-01 00:00:00

abstract：:We measured serum levels of soluble (s) P-selectin and thromboxane B2 (TxB2) in patients with lung cancer treated with gefitinib, and investigated the effect of low-dose aspirin on some adverse effects of gefitinib. The serum levels of sP-selectin and TxB2 increased significantly in all patients who received gefitinib...

journal_title：Anti-cancer drugs

authors： Kanazawa S,Yamaguchi K,Kinoshita Y,Muramatsu M,Komiyama Y,Nomura S

更新日期：2006-04-01 00:00:00

abstract：:Liver X receptor (LXR) has been exploited widely as a drug target in breast cancer treatment, and various mechanisms underlying the effects of LXR in this area are well studied. The activated LXR plays important roles in estrogen receptor α (ERα) breast cancer cells, such as reducing cell proliferation and arresting c...

journal_title：Anti-cancer drugs

authors： Wu Y,Yu DD,Yan DL,Hu Y,Chen D,Liu Y,Zhang HD,Yu SR,Cao HX,Feng JF

更新日期：2016-06-01 00:00:00

abstract：:9-Nitrocamptothecin (9NC) is a water-insoluble topoisomerase I inhibitor with a broad antitumor activity in animal models. To determine the maximum tolerated oral dose (MTD), a phase I study was performed in patients with advanced cancer refractory to conventional chemotherapy. 9NC was administered orally with escalat...

journal_title：Anti-cancer drugs

authors： Verschraegen CF,Natelson EA,Giovanella BC,Kavanagh JJ,Kudelka AP,Freedman RS,Edwards CL,Ende K,Stehlin JS

更新日期：1998-01-01 00:00:00

abstract：:The present study aimed to entrap and characterize the morphology and antitumor effects of a dermaseptin (DStomo01) peptide in chitosan nanoparticles, in vitro. DStomo01 nanoparticles showed moderate polydispersivity, excellent colloidal stability, and slow release. It was noted that free DStomo01 induced DNA fragment...

journal_title：Anti-cancer drugs

authors： Medeiros KA,Joanitti GA,Silva LP

更新日期：2014-03-01 00:00:00

abstract：:Venetoclax is a first-in-class orally available, B-cell lymphoma (BCL)-2 inhibitor indicated for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (CLL) harboring the 17p deletion. We used a novel approach for evaluating venetoclax pharmacokinetics using only sparse sampling in 155 patien...

journal_title：Anti-cancer drugs

authors： Salem AH,Dunbar M,Agarwal SK

更新日期：2017-09-01 00:00:00

abstract：:Telomerase is an enzyme responsible for telomere maintenance in almost all human cancer cells, but generally not expressed in somatic ones. Therefore, antitelomerase therapy is a potentially revolutionary therapeutic strategy, and the antitumor activity of telomerase inhibitors (TI) has been studied extensively recent...

journal_title：Anti-cancer drugs

authors： Morais KS,Guimarãesb AFR,Ramos DAR,Silva FP,de Oliveira DM

更新日期：2017-08-01 00:00:00